Primary Tumour Resection and PRRT of NEN Stage IV - Are There Differences in Grading? Abstract #2845

Introduction: The resection of primary tumours (PT) in patients with stage IV NEN is still a matter of debate. The resection of tumours with a low proliferation index (G1/G2) is more accepted then the resection of high proliferative tumours (G3-NET / G3-NEC).
Aim(s): To find out if resection of PT with different grading (G1-G3) prior to PRRT is associated with better overall survival (OS).
Materials and methods: In 2004, a prospective database of NEN patients studied with 68Ga-SSTR PET/CT was initiated. From2004 until 2014, we analyzed the data of 889 patients with NEN (G1-3) stage IV treated with PRRT (at least 1 cycle). PT was removed in 486 / 889 patients, whereas 403 / 889 patients did not undergo PT resection before PRRT. Median overall-survival (mOS) was determined by 68Ga-SSTR-PET/CT applying RECIST and EORTC.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: PD Dr. Daniel Kaemmerer

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2777 Tumor-to-Liver Ratio of Ga-68-DOTATOC PET/CT as a Prognostic Parameter in Metastatic, Well-Differentiated Gastroenteropancreatic-Neuroendocrine Tumor Patients Who Received Lanreotide Therapy
Introduction: Lanreotide is a long-acting somatostatin analogue with proven antitumor effect against metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors (GEP-NETs). Ga-68-DOTATOC PET/CT is a sensitive imaging technique for NETs by targeting somatostatin receptors.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Yong-Il Kim
#2784 Predictive Factors of Tumor Recurrence after Radical Surgery for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs): Identification of High-Risk Subgroups
Introduction: There is no proven role for adjuvant medical therapy after curative surgery (R0) for GEP-NENs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Roberta Elisa Rossi
#2832 Lymph Node Merkel Cell Carcinoma without Primary: Long Term Survival
Introduction: Merkel cell carcinoma (MCC) is a rare aggressive cutaneous neuroendocrine carcinoma with a high rate of metastasis. Approximately 5% of MCC are found in the lymph nodes (LNs) without a primary tumor on the skin.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Mohammed Alaeddine Saidi
Authors: Saidi M A, Ghomari S, ...
#2985 Peptide Receptor Radionuclide Therapy (PRRT) Outcome Prediction in Neuroendocrine Tumors (NET): Could Radiomic Features Analysis of 68Ga-DOTATOC PET/CT Have a Roll?
Introduction: The PRRT is an effective treatment for NET, but the selection of a good candidate is a very important step.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Virginia Liberini
#3031 Primitive Peripheral Neuroectodermal Tumor: Case Report
Introduction: Primitive neuroectodermal tumors belong to the family of Ewing sarcomatous tumors, all derived from the same stem cell. The cells of the neural crest are believed to be at the origin of these tumors. The predilection sites of these sarcomas are para-vertebral region, chest wall and the distal ends. The positive diagnosis of primary neuroectodermal tumors requires the contribution of histopathology, immunohistochemistry and cytogenetics.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Boublenza Ikram
Authors: Ikram B, Soumeya G, ...